About us
About us

Get to know us

The Forbion Ethos

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients.

Main areas of scientific interest

Forbion contributes to the health and well-being of patients worldwide. Our companies have positively affected almost half a million patients in the areas of:

  • Autoimmune & Inflammation

  • Cardiovascular/Metabolic

  • Central nervous system

  • Digestive & Renal

  • Oncology

  • Ophthamology

  • Orphan/rare disease

  • Respiratory

Forbion then and now

Forbion was born out of ABN AMRO Capital Life Sciences. Today, to emphasize its value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits.

Forbion currently manages €3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees.

Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.

  • € 3bn
    Across ten closed-end funds
  • € 750m
    Forbion Ventures VI
  • € 600m
    Forbion Growth Opportunities Fund II
  • 43
    Active portfolio companies

The Forbion Strategy

Cornerstone investor with a strong platform of funds. Supporting biotech companies throughout all stages of development

Impacting the future of medicine

Forbion impacts the health and well-being of patients worldwide by supporting sustainable and responsible development principles. Our impact can be recognized in various areas.

A Global Team

The Forbion team consists of 46 people of diverse nationalities across three offices in The Netherlands, Germany and Singapore. Our unique blend of investment professionals and drug development experts makes us one of the largest team of life sciences professionals in Europe. Furthermore, Forbion has dedicated investment teams for each platform strategy, with broad support in finance, legal and operations.

World map World map
  • Forbion Offices
  • Team Member Nationalities

Subscribe